阅读说明：本技术 一种具有抗非小细胞肺癌作用的药物及其用途 (A kind of drug and application thereof with anti-non-small cell lung cancer effect ) 是由 陈美姿 周融融 胡洪波 彭咏波 于 2019-07-10 设计创作，主要内容包括：本发明属于药物治疗领域,公开了一种具有抗非小细胞肺癌作用的药物及其用途。该药物的活性成分为非布司他。本发明首次提出非布司他用于治疗非小细胞肺癌的方法及其在制备治疗非小细胞肺癌药物中的应用,非布司他应用于治疗非小细胞肺癌将是一个很有前景的老药新用途临床策略,将使更多的非小细胞肺癌患者获益。(The invention belongs to drug therapy fields, disclose a kind of drug and application thereof with anti-non-small cell lung cancer effect.The active constituent of the drug is Febustat.The method for being used to treat non-small cell lung cancer present invention firstly provides Febustat and its application in preparation treatment non-small cell lung cancer drug, it will be a very promising use of approved drugs for nonapproved uses clinical strategy that Febustat, which is applied to treatment non-small cell lung cancer, benefit more Patients with Non-small-cell Lung.)

1. a kind of drug with anti-non-small cell lung cancer effect, it is characterised in that: the active constituent of the drug is Febustat.

2. a kind of drug with anti-non-small cell lung cancer effect according to claim 1, it is characterised in that: the drug Also contain pharmaceutically acceptable carrier.

3. drug according to claim 1 is preparing the purposes in anti-non-small cell lung cancer drug.

Technical field

The invention belongs to drug therapy field, in particular to a kind of drug with anti-non-small cell lung cancer effect and its Purposes.

Background technique

Cancer is to seriously endanger a big chronic disease of human health, has become the second largest killer for being only second to cardiovascular disease. Lung cancer is first of the highest malignant tumour of morbidity and mortality, wherein non-small cell lung cancer (Non-small cell lung Cancer, abbreviation NSCLC) account for the 80% of lung cancer.Currently, the primary treatments of non-small cell lung cancer are still chemotherapy.For There are EGFR^L858RThere are the patient of different deletion mutations (common Asia, women, non-suctions for mutation or EGFR19 exon Cigarette, Patients with Non-small-cell Lung) apply Gefitinib (Gefitinib, Gef；Also known as Iressa) targeted therapy effect is preferable.

The biggish puzzlement of the generally existing side effect of chemotherapy of tumors, because it is while killing tumour cell also to normal Cell has stronger lethal effect, and many tumor patients can not be resistant to the chemotherapy of larger dose and cause treatment that can not continue And it is dead.Although targeted drug Gefitinib has certain therapeutic effect to the part EGFR patient that there is mutation, in clinic On also achieve significant curative effect, but using after several courses for the treatment of, can also generate certain drug resistance and side effect, patient is general It can occur to recur in 1~2 year or shift, or generate new mutation and drug resistance is generated to Gefitinib, so, even if making It still cannot effectively be improved 5 years of Patients with Non-small-cell Lung with Gefitinib (tyrosine kinase inhibitor) treatment Overall survival.Some researches show that certain Chinese traditional medicine molecules can reduce the drug resistance that anticancer drug generates in use and secondary work With so that improving it treats effectiveness.

Febustat (Febuxostat, abbreviation FBS), Fei Buzuosita, entitled the 2- [(3- cyano -4- isobutyl of chemistry Oxygroup) phenyl] -4- methyl-5-thiazole carboxylic acid is xanthine oxidase (XO) inhibitor, suitable for the height with gout symptom The long-term treatment of uricacidemia, clinical application are significantly safe.

Summary of the invention

In order to overcome shortcoming and defect existing in the prior art, the primary purpose of the present invention is that providing one kind has The drug of anti-non-small cell lung cancer effect.

Another object of the present invention is to provide a kind of purposes of said medicine.

The purpose of the invention is achieved by the following technical solution:

A kind of drug with anti-non-small cell lung cancer effect, the active constituent of the drug are Febustat.

The drug also contains pharmaceutically acceptable carrier.

The drug is prepared by conventional fabrication process.

Above-mentioned drug is preparing the purposes in anti-non-small cell lung cancer drug.

The drug can be used for the drug therapy of mammal including people.

The present invention have the advantages that compared with prior art as follows protrude and the utility model has the advantages that

Inventor is respectively to three kinds of different types of non-small cell lung cancer cell strain NCI-H1975 (EGFR^L858R/T790M), HCC827(EGFR^E746-A750del) and A549 (EGFR^WT) it is that model carries out external MTT screening, find it with very strong anti- Proliferation activity and be in good timeliness and dose-effect relationship, has good clinical application development prospect again.Meanwhile etc. effects Dose evaluation shows that combination drug not yet increases the toxicity of normal liver cell L-O2.

Detailed description of the invention

Fig. 1 is figure compared with Febustat is acted on altogether with Gefitinib to the degradation of EGFR protein expression.

Fig. 2 is that Febustat and Gefitinib are applied alone and are combined and inhibit situation map to H1975 mdr cell transplantable tumor.

Fig. 3 is that Febustat and Gefitinib are applied alone and are combined to H1975 cell transplantation tumor nude mice weight change figure.

Specific embodiment

Present invention will now be described in further detail with reference to the embodiments and the accompanying drawings, but embodiments of the present invention are not It is limited to this.